Zhang X, Shen J, Huang M, Li R, et al. Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials. Front Immunol 2024;15:1507977.
PMID: 39712004